Latest news with #ParkHaBiologicalTechnologyCo.
Yahoo
26-06-2025
- Business
- Yahoo
Park Ha Biological Technology Co., Ltd.'s (NASDAQ:PHH) most bullish insider is CEO Xiaoqiu Zhang, and their holdings value went up by 35% last week
Significant insider control over Park Ha Biological Technology implies vested interests in company growth Xiaoqiu Zhang owns 72% of the company Using data from company's past performance alongside ownership research, one can better assess the future performance of a company Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To get a sense of who is truly in control of Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 72% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. As a result, insiders were the biggest beneficiaries of last week's 35% gain. In the chart below, we zoom in on the different ownership groups of Park Ha Biological Technology. See our latest analysis for Park Ha Biological Technology Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them. There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money. Park Ha Biological Technology's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely. Park Ha Biological Technology is not owned by hedge funds. The company's CEO Xiaoqiu Zhang is the largest shareholder with 72% of shares outstanding. This implies that they possess majority interests and have significant control over the company. Investors usually consider it a good sign when the company leadership has such a significant stake, as this is widely perceived to increase the chance that the management will act in the best interests of the company. With 9.5% and 0.06% of the shares outstanding respectively, Changxin International Limited Partnership and Geode Capital Management, LLC are the second and third largest shareholders. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. It seems that insiders own more than half the Park Ha Biological Technology Co., Ltd. stock. This gives them a lot of power. That means they own US$616m worth of shares in the US$853m company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling. The general public, who are usually individual investors, hold a 18% stake in Park Ha Biological Technology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. It seems that Private Companies own 9.5%, of the Park Ha Biological Technology stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company. It's always worth thinking about the different groups who own shares in a company. But to understand Park Ha Biological Technology better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Park Ha Biological Technology (at least 1 which is significant) , and understanding them should be part of your investment process. Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
30-04-2025
- Business
- Yahoo
Why Park Ha Biological Technology Co., Ltd. (PHH) is Surging in 2025
We recently published a list of . In this article, we are going to take a look at where Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) stands against other consumer defensive stocks that are surging in 2025. The stock market has taken a sharp turn after two years of blockbuster gains, and many investors have felt uneasy. These investors are now turning to consumer defensive stocks due to growth stocks sputtering amid a new wave of tariffs rattling global trade. Consumer defensive stocks provide essential goods and services that people rely on regardless of economic conditions and are more insulated during market downturns. Investors have piled into consumer defensive stocks for that reason, and it's a good idea to look into the biggest winners in this sector. Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified Why These 15 Healthcare Stocks Are Surging in 2025 in another article. For this article, I screened the best-performing consumer defensive stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). vgstudio/ Number of Hedge Fund Holders In Q4 2024: 1 Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) develops and sells private-label skincare products and operates franchise beauty stores, mainly in China. The stock is up significantly so far in 2025, with the most significant driver being its successful initial public offering on December 27, 2024, where it raised $4.8 million at $4.00 per share. After the IPO, the stock surged rapidly. The company's rapid price appreciation is largely attributed to post-IPO momentum and heightened retail interest, particularly from overseas investors, as well as its niche positioning in the skincare market focused on solutions for problematic skin and a dual business model combining direct sales with franchise expansion. Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) stock is up 119.08% year-to-date. Overall, PHH ranks 3rd on our list of consumer defensive stocks that are surging in 2025. While we acknowledge the potential of PHH as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PHH but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-03-2025
- Business
- Yahoo
Why Park Ha Biological Technology Co., Ltd. (PHH) Soared Last Week
We recently compiled a list of the . In this article, we are going to take a look at where Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week, clocking in impressive gains on the back of a flurry of catalysts that boosted investing appetite. We named last week's top 10 performers that outperformed the Russell 2000 index, which dropped by 4.04 percent week-on-week. Among them, one firm particularly stood out with its outstanding 317-percent jump, thanks to a $1-billion deal that could fuel its growth prospects. To come up with the list, we considered the stocks with the highest week-on-week change, comparing their share prices on March 7 and February 28. We classified micro-cap companies as those with a market capitalization below $300 million and small-cap firms as those with a market capitalization below $2 billion. A photograph of a customer testing out different products in the skincare aisle at a store. Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) surged by 46.7 percent last week to end at $7.69 on Friday versus the $5.24 closing week-on-week despite the lack of fresh catalysts to boost investing appetite. Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH), a China-based company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, is also a newly listed firm on the US stock exchange, having debuted on December 27, 2024. From its initial public offering price of $4 apiece, Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH)'s latest stock price already marked a 92.25-percent jump, signaling investor optimism. Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) was able to raise $4.8 million from its IPO, with net proceeds intended to be used for expanding the scale of directly-owned stores in the PRC, purchasing existing product patents to develop proprietary products, and acquiring ingredient suppliers to reduce production costs over the long term. Overall PHH ranks 8th on our list of last week's top performers. While we acknowledge the potential of PHH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PHH but trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
